MTOR and cancer: Numerous oncogenic signaling pathways within cancer cells contribute to resistance against immune checkpoint therapy, including receptor tyrosine kinases (RTKs), MAPK, PI3K-AKT-mTOR, JAK-STAT, Hippo, and Wnt pathways [6].